Fy phenotype and gender determine plasma levels of monocyte chemotactic protein.
BACKGROUND
In vitro studies indicate that the Fy blood group system antigens serve as receptors for chemokines such as monocyte chemotactic protein-1 (MCP-1) and RANTES. However, it is unclear whether subjects with the Fy(a-b-) phenotype exhibit altered clearance and hence altered plasma levels of chemo-kines, because they still express Fy on endothelial cells.


METHODS
To clarify a possible in vivo role of Fy on RBCs in the regulation of chemo-kine levels, healthy young volunteers of common Fy phenotypes were compared in a cross-sectional study.


RESULTS
More than 90 percent of the 34 subjects of African origin were Fy(a-b-), one black volunteer was Fy(a+b-), and two were Fy(a-b+). As expected, all 65 white volunteers were positive for either Fy(a) and/or Fy(b). Unexpectedly, persons expressing either Fy(a) and/or Fy(b) had significantly higher plasma levels of MCP-1 than Fy(a-b-) volunteers (women: 154 vs. 110 ng/L, p<0.01; men: 179 vs. 169 ng/L, p = 0.03). Surprisingly, plasma levels of MCP-1 were found to be sex-dependent: median MCP-1 levels averaged 180 ng per L in men but only 139 ng per L in women (p<0.001). Further, MCP-1 levels decreased significantly throughout the menstrual cycle of 18 women studied longitudinally.


CONCLUSIONS
MCP-1 levels are about 30 percent higher in men than in premenopausal women, and MCP-1 levels are also higher in persons with RBCs expressing Fy antigens than in Fy(a-b-) persons. These findings have direct implications for the concept and interpretation of clinical studies measuring MCP-1 levels; the role of the observed differences in MCP-1 levels for the pathogenesis of MCP-1-dependent diseases, such as atherosclerosis, merits further investigation.
Jilma-Stohlawetz
P
P
Department of Clinical Pharmacology (The Adhesion Research Group Elaborating Therapeutics), University Vienna, Austria.
Homoncik
M
M
Drucker
C
C
Marsik
C
C
Rot
A
A
Mayr
W R
WR
Seibold
B
B
Jilma
B
B
D000328:Adult; D018955:CD36 Antigens / Q000276:immunology*; D005260:Female; D006386:Hemagglutination Tests; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000276:immunology*; D007518:Isoantibodies / Q000276:immunology*; D017713:Platelet Transfusion; D013921:Thrombocytopenia / Q000276:immunology* / Q000628:therapy
D018955:CD36 Antigens; D007518:Isoantibodies